Climate Change Data

Environmental Metrics

ESG Focus Areas

• Environmental impact
• Employee well-being
• Ethical guidelines
• Responsible consumption and production
• Good health and well-being

Environmental Achievements

• Reduced patient visits to clinics, leading to reduced CO2 emissions (indirectly through PharmaShell®'s extended release)
• Reduced use of disposable products like syringes (indirectly through PharmaShell®'s extended release)

Social Achievements

• Improved patient adherence to treatment through long-acting injectable drugs, leading to better health outcomes
• Simplified everyday life for patients with fewer clinic visits
• Maintained a low level of staff turnover

Governance Achievements

• Conducted business in accordance with regulatory guidelines and industry standards
• Established a nomination committee ahead of the 2023 AGM
• Implemented a warrant-based incentive scheme for employees

Climate Goals & Targets

Environmental Challenges

• Risks related to drug development (early-stage projects, uncertainty of study outcomes)
• Regulatory risk (delayed or missing approvals)
• Business and operational risks (dependence on collaborative partners, potential partner non-fulfillment of obligations)
• Future capital needs (negative cash flow until licensing agreements generate revenue)
• Technological risk (PharmaShell® technology not working on all drugs, potential medical risks associated with PharmaShell® material)
• Dependence on key people
• Dependence on suppliers for ALD equipment and pharmaceutical substances
• Industry risks (commercially unproven technology, competition)
• Legal risks (intellectual property rights, product liability)

Mitigation Strategies

• Continuous monitoring of developments and assessment of risks
• Careful management of resources and investments
• Active work on maintaining and developing existing partnerships and identifying new partners
• Securing long-term financing through agreements and addition of Novo Nordisk to the shareholder list
• Postponing planned investments and activities to ensure sufficient cash flow
• Raising capital or agreements on licenses and/or exclusivity regarding the PharmaShell technology
• Extensive preclinical studies to ensure technology efficacy and safety
• Building up an organization with qualified people
• Active work with the patent portfolio

Supply Chain Management

Responsible Procurement

• Considering environmental criteria when choosing suppliers

Climate-Related Risks & Opportunities

UN Sustainable Development Goals

• Goal 3: Good health and well-being
• Goal 5: Gender equality
• Goal 8: Decent work and economic growth
• Goal 12: Responsible consumption and production

Nanexa's products and PharmaShell® contribute to better health, gender equality in the workplace, decent work conditions, and responsible consumption and production through reduced patient visits and disposable product use.

Sustainable Products & Innovation

• PharmaShell® drug delivery system

Environmental Metrics

ESG Focus Areas

• Sustainability

Environmental Achievements

• Reduced the number of plastic syringes and other components, thus reducing the impact on the environment. Depot medicines reduce waste by reducing the need for frequent medication administration.

Social Achievements

• Improved patient adherence to treatment through long-acting depot drugs, making everyday life easier for patients and freeing up resources for healthcare providers. Improved treatment efficacy due to greater adherence.

Governance Achievements

• Not disclosed

Climate Goals & Targets

Environmental Challenges

• The Board of Directors believes that the company's current working capital and cash are not sufficient to finance the business for the next 12 months.

Mitigation Strategies

• Continuously evaluating various opportunities to secure long-term financing through agreements with partners and possible injection of external capital.

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement

• Not disclosed

Climate-Related Risks & Opportunities

Physical Risks

• Not disclosed

Transition Risks

• Not disclosed

Opportunities

• Not disclosed

Reporting Standards

Frameworks Used: Null

Certifications: Null

Third-party Assurance: Not disclosed

UN Sustainable Development Goals

• Not disclosed

Not disclosed

Sustainable Products & Innovation

• Long-acting injectable drugs based on PharmaShell®

Awards & Recognition

• Not disclosed